These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36217590)

  • 1. Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis.
    Mi Z; Zhang Y; Feng Z; Liu J; Wu J; Tan H; Ma X; Liu Z; Rong P
    Artif Cells Nanomed Biotechnol; 2022 Dec; 50(1):301-309. PubMed ID: 36217590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.
    Zhou X; Yao Z; Bai H; Duan J; Wang Z; Wang X; Zhang X; Xu J; Fei K; Zhang Z; Tan F; Xue Q; Gao S; Gao Y; Wang J; He J
    Lancet Oncol; 2021 Sep; 22(9):1265-1274. PubMed ID: 34391508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis.
    Huang S; Zheng G; Yang K
    World J Surg Oncol; 2023 Nov; 21(1):349. PubMed ID: 37926852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
    Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
    Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicities associated with immune checkpoint inhibitors: a systematic study.
    Kong X; Chen L; Su Z; Sullivan RJ; Blum SM; Qi Z; Liu Y; Huo Y; Fang Y; Zhang L; Gao J; Wang J
    Int J Surg; 2023 Jun; 109(6):1753-1768. PubMed ID: 37132038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular toxicity with CTLA-4 inhibitors in cancer patients: A meta-analysis.
    Liu H; Fu L; Jin S; Ye X; Chen Y; Pu S; Xue Y
    Cancer Innov; 2024 Jun; 3(3):e116. PubMed ID: 38947758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.
    Gu L; Khadaroo PA; Su H; Kong L; Chen L; Wang X; Li X; Zhu H; Zhong X; Pan J; Chen M
    BMC Cancer; 2019 Jun; 19(1):559. PubMed ID: 31182049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
    Liu S; Gao W; Ning Y; Zou X; Zhang W; Zeng L; Liu J
    Front Immunol; 2022; 13():908173. PubMed ID: 35880172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis.
    Jin C; Zhu X; Huang X; Gong T; Wei Z; You J
    J Comp Eff Res; 2022 Feb; 11(3):203-212. PubMed ID: 35023361
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
    Wang Y; Zhou S; Yang F; Qi X; Wang X; Guan X; Shen C; Duma N; Vera Aguilera J; Chintakuntlawar A; Price KA; Molina JR; Pagliaro LC; Halfdanarson TR; Grothey A; Markovic SN; Nowakowski GS; Ansell SM; Wang ML
    JAMA Oncol; 2019 Jul; 5(7):1008-1019. PubMed ID: 31021376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis.
    Hu J; Tian R; Ma Y; Zhen H; Ma X; Su Q; Cao B
    Front Oncol; 2021; 11():645245. PubMed ID: 34123795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis.
    Wu K; Yi M; Qin S; Chu Q; Zheng X; Wu K
    Exp Hematol Oncol; 2019; 8():26. PubMed ID: 31673481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.
    Liu M; Cheng X; Ni R; Zheng B; Huang S; Yang J
    Front Immunol; 2022; 13():1006860. PubMed ID: 36189211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
    Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
    JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials.
    Ge Y; Zhang H; Weygant N; Yao J
    Front Pharmacol; 2021; 12():640099. PubMed ID: 34447305
    [No Abstract]   [Full Text] [Related]  

  • 20. The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Bishay K; Tandon P; Bourassa-Blanchette S; Laurie SA; McCurdy JD
    Curr Oncol; 2020 Oct; 27(5):e486-e494. PubMed ID: 33173388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.